Clinical Trials Logo

Clinical Trial Summary

Primary objective: • To assess the efficacy of reparixin compared to placebo in limiting CRF in adult patients with locally advanced or metastatic breast cancer undergoing single-agent taxane chemotherapy, using FACITFatigue scale. The secondary objectives are: - To evaluate change in Quality of Life in the two treatment arms - To assess the percentage of patients treated with reparixin compared to placebo delaying and discontinuing chemotherapy - To assess Patient Global Impression of Severity (PGI-S) score and Patient Global Impression of Change (PGI-C) score associated with reparixin compared to placebo - To assess the effect of reparixin compared to placebo on ECOG PS - To assess the effects of reparixin vs placebo on Objective Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS) The safety objective is: • To assess the safety and tolerability of reparixin in adult patients undergoing taxane-containing chemotherapy. The pharmacokinetic (PK) objective is: • To define the PK profile of orally administered reparixin, its metabolites (DF2243Y, DF2188Y, ibuprofen) and concomitant antineoplastic agents (paclitaxel, or nab-paclitaxel or docetaxel) in adult patients with locally advanced or metastatic breast cancer.


Clinical Trial Description

This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled study. It will evenly randomize 68 evaluable men and women adult patients with CRF in locally advanced or metastatic breast cancer who are candidates to start single-agent taxane chemotherapy (paclitaxel, nab-paclitaxel or docetaxel). CRF will be assessed at baseline on a scale from 0 - 10 (with 10 being most severe), enrolling any patient who report a score of 1 - 6. Recruitment will be competitive among the study sites, until the planned number of patients is randomized. Patients will be assigned (1:1) to receive either oral reparixin treatment (1200 mg t.i.d. - treatment group) or masked placebo t.i.d. (control group). Randomization will be stratified by site and according to the type of chemotherapy (paclitaxel vs docetaxel vs nab-paclitaxel). Sparse blood samples will be collected in the whole population for reparixin (and metabolites), docetaxel, nab-paclitaxel, paclitaxel PK analysis. Reparixin or placebo will be administered for 16 weeks or until disease progression, withdrawal of consent or unacceptable toxicity, whichever occurs first. Following the completion of the treatment, or after premature discontinuation during the double-blind phase the patients will be followed up for safety assessments for an additional 30 days after last study therapy administration and will be followed for progressive disease and survival until twelve months after last enrolled subject off treatment, or until trial is terminated for other reasons, whatever occurs first. Number of Patients Sixty-eight (68) evaluable adult patients with CRF with locally advanced or metastatic breast cancer who are candidates to receive single-agent taxane chemotherapy will be included in the study. Assuming that 10% of subjects will not be evaluable for primary analysis, a total of approximately 76 subjects is expected to be enrolled. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05212701
Study type Interventional
Source Dompé Farmaceutici S.p.A
Contact Maria De Pizzol, PhD
Phone +39 02 583831
Email [email protected]
Status Recruiting
Phase Phase 2
Start date April 19, 2022
Completion date July 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05546476 - Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 Phase 2
Completed NCT04959214 - The Effect Of Progressıve Relaxatıon Exercıses N/A
Completed NCT04531891 - Utility and Validity of a High-intensity, Intermittent Exercise Protocol N/A
Recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT04960865 - Kinesio Taping and Calf Muscle Fatigue N/A
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Not yet recruiting NCT05487131 - Neuromodulation and Fatigue N/A
Completed NCT04716049 - Effectiveness of Recovery Protocols in Elite Professional Young Soccer Players N/A
Recruiting NCT05457803 - Real-world Momentary Assessment of Kratom Use Accompanied by Product Assays: A Natural-history Study for Interdisciplinary Characterization of Kratom Use and Pharmacology
Completed NCT03943212 - The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis N/A
Recruiting NCT05240560 - Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke Phase 2
Not yet recruiting NCT05531734 - MONITORING OF ATTENTION ACCORDING TO FATIGUE IN THE HEALTHY SUBJECT N/A
Not yet recruiting NCT05524441 - Fatigue in Short-Haul Operations
Not yet recruiting NCT05002894 - Effect of Pilates Exercises On Fatigue In Post Menopausal Women N/A
Recruiting NCT04091789 - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea Phase 2
Completed NCT02911649 - Reducing Sedentary Behaviour With Technology N/A
Completed NCT02321358 - Trial of a Behavior Change Intervention to Increase Aerobic and Resistance Exercise and Quality of Life in Older Prostate and Breast Cancer Survivors N/A
Completed NCT03216616 - Guided Self-Management Intervention Targeting Fatigue in Rheumatic Inflammatory Diseases N/A
Completed NCT01919853 - Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker Response Phase 2
Completed NCT01707095 - Bundling and Unbundling the Laparoscopic Electrosurgery Cord With the Camera Cord N/A